Sexuelle Dysfunktion in der psychiatrischen Therapie

Zusammenfassung

Sexuelle Funktionsstörungen stellen eine häufige unerwünschte Nebenwirkung von Psychopharmaka dar, bei männlichen Patienten treten insbesondere die Ejakulationsstörung und die erektile Dysfunktion auf. Trotz ihrer hohen Prävalenz werden sie in der psychiatrischen Diagnostik nicht ausreichend erfasst. Die medikamentöse Compliance kann durch diese Nebenwirkungen deutlich reduziert werden, insbesondere wenn die Patienten die psychotrope Medikation für ihre sexuellen Dysfunktionen verantwortlich machen. Pharmakainduzierte sexuelle Funktionsstörungen können in jeder Phase der menschlichen sexuellen Reaktion auftreten. Grundsätzlich ist zu beachten, dass der pharmakogene vom morbogenen Einfluss getrennt betrachtet werden muss und der Einfluss von Psychopharmaka alleine auf die Sexualität nicht überbewertet werden darf. Bei der Behandlung von antidepressiva-induzierter erektiler Dysfunktion haben sich PDE-5 Hemmer bewährt. Hinsichtlich neuroleptika-induzierter sexueller Funktionsstörungen kann ein Wechsel zu einem nicht-prolaktin erhöhenden Antipsychotikum hilfreich sein.

Summary

Disturbances in sexual functioning are a common side effect in the treatment of psychopharmacological agents. In male patients ejaculatory disturbance and erectile dysfunction are the common complaints on presentation. Despite their high prevalence these disturbances are not consistently documented. Patient compliance can be markedly reduced as a result of such complications, especially when patients associate their medication with such side effects. Pharmacologically induced disturbance of sexual functioning can occur in every stage of human sexual response. As a rule pharmacogenic and illness-related influences must be distinguished, the influence of psychopharmacological agents must not be over-estimated. In treatment of antidepressive-induced erectile dysfunction PDE-5-inhibitors have proven to be very useful. Regarding neuroleptic-induced functional disturbance a change toa non-prolactin elevating antipsychotic agent may be useful.

Schlüsselwörter

Sexuelle Funktionsstörungen - erektile Dysfunktion - Antidepressiva - Neuroleptika

Keywords

Sexual dysfunctions - erectile dysfunction - antidepressants - antipsychotics

• Literatur

• 1 Andersson KE, Wagner G. Physiology of Penile Erection. Physiological Reviews 1995; 75: 191-236.
• 2 Beier K, Bosinski H, Hartmann U, Loewitt K. Sexualmedizin. München: Urban & Fischer; 2001
• 3 Bliesener N, Yokusoglu H, Quednow BB, Klingmuller D, Kuhn KU. Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: a case report. Pharmacopsychiatry 2004; 37: 189-191.
• 4 Bobes J, Garc MPA-Portilla, Rejas J, Hern GNdez, Garcia-Garcia M, Rico-Villademoros F. Porras Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther 2003; 29: 125-147.
• 5 Bodinger L, Hermesh H, Aizenberg D, Valevski A, Marom S, Shiloh R, Gothelf D, Zemishlany Z, Weizman A. Sexual function and behavior in social phobia. J Clin Psychiatry 2002; 63: 874-879.
• 6 Boyarsky BK, Haque W, Rouleau MR, Hirschfeld RM. Sexual functioning in depressed outpatients taking mirtazapine. Depress Anxiety 1999; 09: 175-179.
• 7 Clayton AH. Recognition and assessment of sexual dysfunction associated with depression. J Clin Psychiatry 2001; 62 (Suppl. 03) 5-9.
• 8 Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, Bass KI, Donahue RM, Jamerson BD, Metz A. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002; 63: 357-366.
• 9 Clayton AH, Warnock JK, Kornstein SG, Pinkerton R, Sheldon-Keller A, McGarvey EL. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 2004; 65: 62-67.
• 10 Cohen S, Kuhn KU, Bender S, Erfurth A, Gastpar M, Murafi A, Rothermundt M, Signerski J, Strater B, Teusch L, Weig W, Welling A, Westheide J, Huber TJ. Sexual impairment in psychiatric inpatients: focus on depression. Pharmacopsychiatry 2007; 40: 58-63.
• 11 Dossenbach M, Hodge A, Anders M, Molnar B, Peciukaitiene D, Krupka-Matuszczyk I, Tatu M, Bondar V, Pecenak J, Gorjanc T, McBride M. Prevalence of sexual dysfunction in patients with schizophrenia: international variation and underestimation. Int J Neuropsychopharmacol 2005; 08: 195-201.
• 12 Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. Ann Pharmacother 2002; 36: 1577-1589.
• 13 Halaris A. Neurochemical aspects of the sexual response cycle. CNS Spectr 2003; 08: 211-216.
• 14 Hartmann U, Rüffer-Hesse C. Sexualität und Pharmakotherapie. Arzneimittelinduzierte sexuelle Funktionsstörungen und medikamentöse Optionen zur Behandlung sexueller Dysfunktionen. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2007; 50: 19-32.
• 15 Hellewell JS. Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. J Clin Psychiatry 1999; 60 Suppl 23: 14-19.
• 16 Hövermann P, Nürnbach-Ross B, Albrecht J. Priapismus unter Clozapintherapie. Nervenarzt 1997; 68: 74-76.
• 17 Kaplan H. The new sex therapy. London: Balliere Tindall; 1974
• 18 Kennedy SH, Dickens SE, Eisfeld BS, Bagby RM. Sexual dysfunction before antidepressant therapy in major depression. J Affect Disord 1999; 56: 201-208.
• 19 Kim SC, Seo KK. Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. J Urol 1998; 159: 425-427.
• 20 Knegtering R, Castelein S, Bous H, Van Der Linde J, Bruggeman R, Kluiter H, van den Bosch RJ. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol 2004; 24: 56-61.
• 21 Kockott G, Pfeiffer W. Sexual disorders in nonacute psychiatric outpatients. Compr Psychiatry 1996; 37: 56-61.
• 22 Labbate LA, Croft HA, Oleshansky MA. Antidepressant-related erectile dysfunction: management via avoidance, switching antidepressants, antidotes, and adaptation. J Clin Psychiatry 2003; 64: 11-19.
• 23 Landen M, Eriksson E, Agren H, Fahlen T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 1999; 19: 268-271.
• 24 Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. Jama 1999; 281: 537-544.
• 25 Marthol H, Hilz MJ. Weibliche sexuelle Funktionsstörungen: Klassifikation, Diagnostik und Therapie. Fortschr Neurol Psychiatr 2004; 72: 121-135.
• 26 Medina CA. Clitoral priapism: a rare condition presenting as a cause of vulvar pain. Obstet Gynecol 2002; 100: 1089-1091.
• 27 Meston CM, Frohlich PF. The neurobiology of sexual function. Arch Gen Psychiatry 2000; 57: 1012-1030.
• 28 Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001; 62: 10-21.
• 29 Montgomery SA, Baldwin DS, Riley A. Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction. J Affect Disord 2002; 69: 119-140.
• 30 Moynihan R. The making of a disease: female sexual dysfunction. BMJ 2003; 326: 45-47.
• 31 Müller-Oerlinghausen B, Ringel I. Medikamente als Verursacher sexueller Dysfunktionen. Deutsches Ärzteblatt 2002; 99: A3108-A3115.
• 32 Nurnberg HG, Hensley PL. Sildenafil citrate for the management of antidepressant-associated erectile dysfunction. J Clin Psychiatry 2003; 64: 20-25.
• 33 Perlis RH, Fava M, Nierenberg AA, Pollack MH, Falk WE, Kienke AS, Rosenbaum JF. Strategies for treatment of SSRI-associated sexual dysfunction: a survey of an academic psychopharmacology practice. Harv Rev Psychiatry 2002; 10: 109-114.
• 34 Rothschild AJ. Sexual side effects of antidepressants. J Clin Psychiatry 2000; 61: 28-36.
• 35 Sigusch V. Sexuelle Störungen und ihre Behandlung. 3. Auflage. Stuttgart: Thieme; 2001
• 36 Smith S. Effects of antipsychotics on sexual and endocrine function in women: implications for clinical practice. J Clin Psychopharmacol 2003; 23: S27-32.
• 37 Smith S, O’Keane V, Murray R. Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry 2002; 181: 49-55.
• 38 Stahl SM. The psychopharmacology of sex, Part 1: Neurotransmitters and the 3 phases of the human sexual response. J Clin Psychiatry 2001; 62: 80-81.
• 39 Tenback DE, van Harten PN, Slooff CJ, van Os J. Tardive dyskinesia in schizophrenia is associated with prolactin-related sexual disturbances. Neuropsychopharmacology 2006; 31: 1832-1837.
• 40 Weig W. Sexuelle Funktionsstörungen aus nervenärztlicher Perspektive. Nervenarzt 2006; 77: 101-109.
• 41 Westheide J, Cohen S, Bender S, Cooper-Mahkorn D, Erfurth A, Gastpar M, Huber TJ, Maier W, Murafi A, Rothermund M, Signerski J, Sträter B, Teusch L, Weig W, Welling A, Kühn KU. Sexual dysfunction in psychiatric inpatients. The role of antipsychotic medication. Pharmacopsychiatry. 2007 in Druck.
• 42 Wirshing DA, Pierre JM, Marder SR, Saunders CS, Wirshing WC. Sexual side effects of novel antipsychotic medications. Schizophr Res 2002; 56: 25-30.
• 43 Zajecka J. Strategies for the treatment of antidepressant-related sexual dysfunction. J Clin Psychiatry 2001; 62: 35-43.